Directors

Dave Summa, Acumen Pharmaceuticals

Acumen logo

David Summa is currently the President and CEO of Acumen Pharmaceuticals, a pre-clinical drug development company that is developing the first effective therapeutics and diagnostics that prevent Alzheimer's disease.

Prior to joining Acumen, Dave was the President and CEO of Mendel Biotechnology, a successful genomics company that was the first to functionally characterize all the transcription factors in arabidopsis thaliana. Mendel's traits now form the core of the Monsanto product pipeline.

Before joining the ranks of Bay Area biotech entrepreneurs, Dave was a Vice President at Monsanto where he created Renessen, the joint venture between Cargill and Monsanto.

Prior to joining Monsanto, Dave was a partner at McKinsey & Company, Inc. where he was the global leader of the Innovation Practice. Dave received his BS and MS from MIT in the department of Chemical Engineering.